High Prevalence of Brain Tumor and R&D of New Drugs to Augment Growth of Anaplastic Astrocytoma Treatment Market

 

Anaplastic Astrocytoma Treatment

High prevalence of brain tumor is expected to propel growth of the anaplastic astrocytoma treatment market. For instance, according to The Central Brain Tumor Registry of the United States (2020 CBTRUS Statistical Report), the incidence rate of all primary malignant and non-malignant brain and other central nervous system tumors in the U.S was 23.79 cases per 100,000 for a total count of 415,411 incident tumors.

Moreover, R&D of new drugs is also expected to aid in growth of the market. For instance, in April 2020, Mateon Therapeutics Inc. announced the publication of a peer-reviewed research article reporting the analysis of the long-term follow-up data on the recalcitrant/resistant anaplastic astrocytoma patient subpopulation treated in the NCT00431561 study, in the oncology journal Cancer Reports and Reviews. Similarly, in December 2020, KIYATEC, Inc. announced the first clinical use of its response-prediction test to improve outcomes in relapsed brain cancer patients.

Adoption of combination therapies is expected to offer lucrative growth opportunities for players in the anaplastic astrocytoma treatment market. For instance, in January 2021, Adastra Pharmaceuticals announced that its Phase Ib trial of oral small molecule drug zotiraciclib in combination with the current standard of care, temozolomide, deminstrted positive results in the treatment of patients with recurrent high-grade gliomas (recurrent anaplastic astrocytoma and recurrent glioblastoma). Moreover, increasing number of treatment centers for brain tumors is also expected to aid in growth of the market. For instance, in March 2020, MagForce AG, a developer of medical devices that generate magnetic hyperthermia to treat cancer, and the Hufeland Klinikum GmbH, a provider of general medical and surgical hospital services, announced the conclusion of a joint cooperation agreement and the planned opening of a NanoTherm treatment center for brain tumors at the Mühlhausen site in Thuringia, Germany.

The anaplastic astrocytoma treatment market is witnessing increasing investment for R&D in the treatment of anaplastic astrocytoma. For instance, in October 2020, Orbus Therapeutics Inc. raised US$ 71 million in Series A financing for R&D in the treatment of anaplastic astrocytoma.

Competitive Analysis

Major players operating in the anaplastic astrocytoma treatment market include, Merck & Co., Inc., Teva Pharmaceutical Industries Ltd., Adastra Pharmaceuticals, KIYATEC, Inc., Mateon Therapeutics Inc., Orbus Therapeutics Inc., Mylan N.V., Pfizer, Inc., and Novartis AG.

Major players operating in the anaplastic astrocytoma treatment market are focused on R&D to expand their product portfolio. For instance, in March 2021, Orbus Therapeutics Inc. announced a positive outcome of the pre-planned interim analysis for futility in its Phase 3 STELLAR clinical study of eflornithine in patients with recurrent anaplastic astrocytoma.